Moderna

BIOVECTRA, part of Agilent Technologies, has partnered with Revolution Biomanufacturing to provide integrated mRNA sequence design and GMP manufacturing services.

Moderna has dosed the first patient with mRNA-2808, an investigational mRNA-based T-cell engager therapy for relapsed or refractory multiple myeloma, marking the company's first T-cell engager to reach clinical testing.

Moderna stock jumped as much as 12% following reports that the company is in discussions with at least one large pharmaceutical company about a potential deal of significant scope.

4basebio PLC announces that a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA therapy developed using the company's proprietary opDNA® template following FDA IND approval.

Moderna's mRNA-1345 RSV vaccine demonstrated safety and efficacy in a Phase III trial of 150 solid organ transplant recipients, with adverse events being mostly grade 1-2 and resolving within 2-3 days.

Moderna's Phase 3 trial of mRNA-1647, an investigational cytomegalovirus vaccine, failed to meet its primary efficacy endpoint of preventing CMV infection in seronegative women aged 16-40.

Monash University researchers have uncovered the genetic code governing how mutations affect RNA splicing, a critical cellular process for protein production.

Moderna's seasonal flu vaccine mRNA-1010 demonstrated 26.6% relative vaccine efficacy compared to standard vaccines in adults aged 50 and above, meeting prespecified superiority criteria.

A new study reveals that mRNA COVID-19 vaccines from Pfizer/BioNTech and Moderna nearly double survival rates for lung cancer patients receiving immunotherapies.

Moderna presented new data on mRNA-4359, which is rapidly advancing to become one of the company's newest late-stage oncology assets.